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Abstract
Arsenic trioxide (As2O3) has shown remarkable efficacy for the treatment of multiple myeloma (MM). Histone deacetylases
(HDAC) play an important role in the control of gene expression, and their dysregulation has been linked to myeloma.
Especially, HDAC6, a unique cytoplasmic member of class II, which mainly functions as a-tubulin deacetylase and Hsp90
deacetylase, has become a target for drug development to treat cancer due to its major contribution in oncogenic cell
transformation. However, the mechanisms of action for As2O3 have not yet been defined. In this study, we investigated the
effect of As2O3 on proliferation and apoptosis in human myeloma cell line and primary myeloma cells, and then we studied
that As2O3 exerts antimyeloma effects by inhibiting activity in the a-tubulin and Hsp90 through western blot analysis and
immunoprecipitation. We found that As2O3 acts directly on MM cells at relatively low concentrations of 0.5,2.5 mM, which
effects survival and apoptosis of MM cells. However, As2O3 inhibited HDAC activity at the relatively high concentration and
dose-dependent manner (great than 4 mM). Subsequently, we found that As2O3 treatment in a dose- and time-dependent
fashion markedly increased the level of acetylated a-tubulin and acetylated Hsp90, and inhibited the chaperone association
with IKKa activities and increased degradation of IKKa. Importantly, the loss of IKKa-associated Hsp90 occurred prior to any
detectable loss in the levels of IKKa, indicating a novel pathway by which As2O3 down-regulates HDAC6 to destabilize IKKa
protein via Hsp90 chaperone function. Furthermore, we observed the effect of As2O3 on TNF-a-induced NF-kB signaling
pathway was to significantly reduced phosphorylation of Ser-536 on NF-kB p65. Therefore, our studies provide an important
insight into the molecular mechanism of anti-myeloma activity of As2O3 in HDAC6-Hsp90-IKKa-NFkB signaling axis and the
rationale for As2O3 can be extended readily using all the HDAC associated diseases.
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Introduction
During the last decade, arsenic trioxide (As2O3) has been
demonstrated the efficacy and safety treatment for acute
promyelocytic leukemia (APL) [1,2]. Currently, many trials have
represented that the addition of As2O3 to standard treatment
regimens improves survival outcomes in patients and may allow a
reduction in cytotoxic chemotherapy exposure in other malignan-
cies, particularly multiple myeloma (MM) and myelodysplastic
syndromes (MDS) [3,4,5,6]. Several trials have evaluated the
efficacy of As2O3 in combination with existing MM therapies,
including melphalan, dexamethasone, ascorbic acid, and bortezo-
mib, in relapsed patients [3,4].
Arsenic acts on cells through a variety of mechanisms,
influencing numerous signal transduction pathways and resulting
in a vast range of cellular effects that include apoptosis induction,
growth inhibition, promotion or inhibition of differentiation, and
angiogenesis inhibition [7,8,9,10]. In MM, As2O3 induces
apoptosis of MM cells via caspase-9 and overcomes the protective
effect of IL-6 in the BM milieu by inhibiting JAK-STAT survival
signaling in tumor cells. Moreover, As2O3 reduces tumor necrosis
factor (TNF) a-induced adhesion to bone marrow stromal cells
(BMSCs) and the resultant induced secretion of cytokines (IL-6
and VEGF) that promote MM cell growth, survival, and migration
[8].
Modification of proteins by histone acetyltransferases (HAT) or
histone deacetylases (HDAC) plays an important role in the
control of gene expression, and its dysregulation has been linked to
myeloma and others malignant transformation or diseases [11,12].
To date, eighteen HDAC family members (HDAC1-11 and
SIRT1-7) have been identified and divided into 5 groups: class I
(HDAC1, HDAC2, HDAC3, and HDAC8), class IIa (HDAC4,
HDAC5, HDAC7, and HDAC9), class IIb (HDAC6 and
HDAC10), class III (SIRT family), and class IV (HDAC11)
according to their homology to yeast histone deacetylases. They
play an important role in regulating gene transcription as well as a
variety of cellular functions [13,14]. HDAC6, a unique cytoplas-
mic member of class II, has become a target for drug development
to treat cancer due to its major contribution in oncogenic cell
transformation [12]. Most of the studies focus on its major
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lymphocyte chemotaxis, cellular adhesions, aggresome formation,
EGFR signaling, stress granules in stress response, and growth
factor-induced actin remodeling and endocytosis [15,16]. Hsp90
was the second HDAC6 substrate identified in the cytoplasm after
a-tubulin [17]. Hsp90 is a molecular chaperone that is induced in
response to cellular stress and stabilizes client proteins involved in
cell cycle control and proliferative/anti-apoptotic signaling.
Chaperone Hsp90 has been described as components of the
IKK complex, which associated with its co-chaperone cdc37
behaves as a stabilizing factor of IKK through interaction between
cdc37 and the kinase domains of IKKa and IKKb in NF-kB
signaling [18].
Although As2O3 has been extensively studied as potential anti-
myeloma treatment, the precise functions of As2O3 in the
myeloma cells remain to be defined; especially whether As2O3
could affect activity in HDAC6-Hsp90-IKKa-NFkB signaling
axis. Therefore, in this study we examined As2O3 exerts
antimyeloma effects involving in activity toward cytoplasmic
substrates a-tubulin and Hsp90 of HDAC6, IKK complex, and
then the direct phosphorylation of p65 on NF-kB signaling
pathway, which may provide a novel molecular basis and rationale
for the use of As2O3 in MM treatment.
Results
As2O3 inhibits myeloma cell growth and induces
apoptosis
In order to determine the cell proliferation to As2O3, MM cell
line was treated with drug at the concentration from 0.1 mMt o
64 mM for 24, 48 and 72 hours and four primary myeloma cells
were cultured with As2O3 (0.1,64 mM) for 48 hours (Figure 1).
As2O3 inhibited the growth of MM cells in a dose- and time-
dependent manner (Figure 1A). Fifty percent growth inhibition
(IC50) in NCI-H929 cells at 48 hours was observed with 2.5 mM
As2O3, and As2O3 effects in inhibiting cell growth displayed
IC50#4 mM on primary MM cells (Figure 1B). Taken together,
the results demonstrate As2O3 inhibits the proliferation of MM
cells at the relatively low concentration both in cell line and
primary myeloma cells.
Then we determined the percentage apoptosis of NCI-H929
exposed to As2O3 by flow cytometry using Annexin V FITC/PI
Figure 1. As2O3 inhibits myeloma cells growth. As2O3 with different concentrations (0.1 mM,64 mM) inhibits proliferation of (A) MM cell lines
for 24 hours, 48 hours, and 72 hours and (B) MM patients’ cells for 48 hours. Cell growth inhibition was measured with the CCK-8 reagent, as
described in the Methods. (C) As2O3 induced apoptosis of NCI-H929 cells. Apoptosis rates were determined using Annexin-V/PI staining. Cells were
incubated for 24 or 48 hours with 1 mM,0 mMo fA s 2O3, and the appropriate combination and analyzed by flow cytometry. Data are the mean+SD
for three replicate measurements. * means statistical difference was observed between the treated group and control (P,0.05).
doi:10.1371/journal.pone.0032215.g001
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Annexin V positive cells (apoptotic cells) in As2O3-treated cells
compared to the control. Treatment of NCI-H929 cells with
As2O3 for 48 hours resulted in 3.1% to 89% apoptosis,
respectively, at the dose dependent apoptosis of As2O3 from
0 mMt o1 0mM, with effective dose for 50% apoptosis (ED50)
between 2 mM,5 mM. These results suggest that As2O3 is a
potent inducer of apoptosis in myeloma, particularly at the
relatively low concentration.
As2O3 decreases HDAC activity in myeloma cells
To investigate whether a decrease in histone acetylase activity
could be achieved by As2O3 treatment in the myeloma cells,
enzyme activity was evaluated by colorimetric commercial HDAC
activity assay in NCI-H929 cells. Results are also shown in
Figure 2. Using the same scale for HeLa cell extracts treated or
without trichostatin A as positive and negative control, we found
that the deacetylase activity was significantly decreased in cells
treated with relatively high concentration range from
4 mM,64 mM( p,0.05), however, the deacetylase activity had
no change in cells treated with 0.5 mM,2 mM lower concentra-
tions. When cells treated at the maximum concentration 64 mMi n
this study, the deacetylase activity was inhibited over 70%, which
showed in a concentration-dependent manner.
As2O3 triggers the accumulation of a-tubulin acetylation
HDAC6 has emerged as a major cytoplasmic deacetylase
functioning as a-tubulin deacetylase and Hsp90 deacetylase. To
assess the biologic significance of As2O3 on HDAC6 activity, we
next examined the acetylated a-tubulin level in cells. Since 2.5 mM
and 5 mMA s 2O3 decreased the cell viability to about 50% in cell
line and primary cells, we used these concentrations to further
study the activity of As2O3 in myeloma cells. NCI-H929 cells were
incubated with As2O3 from 1 mMt o1 0mM for 48 hours, and
exposed to As2O3 at 2.5 mM at 24 and 48 hours, respectively. The
whole-cell extracts were then analyzed by western blot. As2O3
treatment in a dose- and time-dependent fashion markedly
increased of acetylated a-tubulin in myeloma cells (Figure 3A
and 3B). Importantly, As2O3 also triggered the accumulation of a-
tubulin acetylation in primary tumor cells with 5 mM for 12 hours
(Figure 3C).
As2O3 induces hyperacetylation of Hsp90 and decreases
IKKa-binding to Hsp90
Next, we determined the second HDAC6 substrate which is the
well-characterized chaperone Hsp90. A potential effect of As2O3
on the Hsp90-IKK interaction was investigated by immunopre-
cipitation (Figure 4). We observed the greater increased accumu-
lation of acetylated Hsp90 in NCI-H929 cells treated with As2O3
at 2.5 mMo r5mM compared to the control (Figure 4A). Since
Hsp90 clients are degraded by the ubiquitin-proteasome pathway
when Hsp90 function is inhibited [19], we investigated the effect in
As2O3-mediated degradation of IKK in myeloma cells. Binding of
Hsp90 to the IKKa was disrupted when cells were treated with
As2O3 2.5 mM for 48 h, while the total Hsp90 in the input
material was not affected and the IKKa protein levels was very
mild decreased during the same time point (Figure 4B). Further-
more, we performed western blot assay and observed that the
IKKa protein was down expression in myeloma cells treated with
As2O3 5 mM, whereas there was ineffective with As2O3 at 2.5 mM
(Figure 4C).
As2O3 inhibits TNF-a-dependent p65 phosphorylation
To examine the effect of As2O3 on the NF-kB activation
pathway, TNF-a was used, which it is relatively well understood of
a potentiated pathway activated agent. The activation of NF-kB
involves the phosphorylation, ubiquitination, and degradation of
the inhibitor of NF-kB( I kBa), which leads to the nuclear
translocation of the p50-p65 subunits of NF-kB followed by p65
phosphorylation, acetylation and methylation, DNA binding, and
gene transcription [20]. Phosphorylation of the p65 subunit of NF-
Figure 2. As2O3 can cause a decrease in HDAC activity. Graphs in the panel are HDAC activity expressed as ODs, in the same scale as the
positive and negative controls that are also HeLa cells extracts with and without trichostatin A treatment. At the bottom are values of As2O3
treatment concentration. * means statistical difference was observed between the treated group and control (P,0.05).
doi:10.1371/journal.pone.0032215.g002
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Stimulus-induced phosphorylation of multiple amino acid residues
in the p65 subunit is required for transcriptional activation of NF-
kB in various cell types [21,22]. Since TNF-a has been shown to
vary significantly phosphorylation of p65 at Ser 536 in the
transactivation domain (TAD) compared to Thr 254, Ser 276, Ser
311, and Ser 529 in a variety of cell types [23], we chose to detect
phosphorylation of p65 at Ser 536 in myeloma cells. NCI-H929
cells were pretreated without or with As2O3 for 6 hours at 2.5 mM,
exposed them to 10 ng/mL TNF-a for different times, and
examined them for p65 by western blot. We observed that TNF-a
induced p65 phosphorylation within 30 minutes, and significantly
suppressed the phosphorylation of p65 with the time-dependent in
overall interval times, importantly As2O3 could further suppressed
p65 phosphorylation in response to TNF-a treatment in myeloma
cells (Figure 5A). Subsequently, we examined the p65 phosphor-
ylation for cells incubated with 2.5 mM, 5 mM, 7.5 mMA s 2O3 for
6 hours and then treated with TNF-a for 20 minutes. We found
that As2O3 inhibited the p65 phosphorylation induced by TNF-a
in dose-dependent matter (Figure 5B).
Discussion
In the present study, we show that the molecular mechanisms of
the action of As2O3 against MM by inhibiting activity in the
cytoplasmic substrates of HDAC6. We first demonstrate that
As2O3 acts directly on MM cells at low concentrations of
0.5 mM,2.5 mM, inhibiting the proliferation of myeloma cells at
time- and dose-dependent fashion, and As2O3 induced apoptosis
in MM cells, as evidenced by an increase in the annexin V-positive
and PI negative apoptotic cell population. These results have been
confirmed and extend previous investigations [8,24,25]. Subse-
quently, we observed As2O3 represses the HDAC activity at the
high concentration with 64 mM markedly reduction HDAC
activity over 70%. Previous studies also suggested that As2O3 at
much high concentration (great than 500 mM) affects multiple
cellular functions via diversely enzyme activity [26], which
represses the NF-kB pathway by inhibiting IKK activity at high
As2O3 concentration [27] whereas lower concentrations were
ineffective for IKK activity [28]. In several leukemia and
lymphoma and solid tumors cells, some studies have reported
that the high concentrations of As2O3 (greater than 10 mM)
treatment activated the Jun N-terminal kinase (JNK) and p38,
members of stress-activated signal transduction pathways, and
resulted in apoptosis [29,30]. Recently study showed that HDAC
inhibitor, scriptaid, induces glioma cell apoptosis through JNK
activation and inhibits telomerase activity [31]. Therefore, we
speculated that the HDAC activity was significantly decreased by
As2O3 treatment at higher concentrations, which might mediate a
stress response involving in JNK activation. Unlike As2O3
activation at low As2O3 concentrations (0.5 mM,2 mM) is
correlated with proliferation and apoptosis induction in myeloma
cells through radical oxygen species–mediated pathways [32,33].
Further detailed mechanism analysis of the HDAC activation at
higher concentration will be required to verify this hypothesis. In
addition, the binding of As2O3 to critical thiol group in the
enzyme, or alternatively, arsenite may alter the structure of the
histone deacetylase complex, which might be attributed to HDAC
inhibition after high-dose As2O3 stress treatments.
Class IIb HDAC6 has emerged as a major cytoplasmic
deacetylase, which mainly functions as a-tubulin deacetylase and
Hsp90 deacetylase [17], thereby regulating cell motility, adhesion
Figure 3. As2O3 triggers the accumulation of a-tubulin acetylation. (A) NCI-H929 cells were cultured with As2O3 (1 mM, 2.5 mM, 5 mM, 7.5 mM
and 10 mM) for 48 hours. (B) NCI-H929 cells were cultured with As2O3 (2.5 mM) for the indicated time periods. (C) Primary tumor cells from MM
patients were cultured with As2O3 (5 mM) for 12 hours.
doi:10.1371/journal.pone.0032215.g003
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aggresomes and thus represents a protective cellular response to
cytotoxic effects of misfolded protein [34]. Our results showed that
treatment of myeloma cells with As2O3, followed by immunoblot-
ting of the cell extracts with anti-(acetylated tubulin) antibody
resulted in markedly increased a-tubulin acetylation in a dose- and
time- dependent fashion. Importantly, As2O3 also triggered the
accumulation of a-tubulin acetylation in primary tumor cells.
There is evidence that the overexpression of HDAC6 leads to a
global deacetylation of a-tubulin, whereas a decrease in HDAC6
increases a-tubulin acetylation [35]. Therefore, we suggested that
As2O3 inhibited HDAC6 through enhanced accumulation of
acetylated a-tubulin. Previous studies showed that HDAC6
acetylated tubulin via its tubulin acetylase domain and then
resulted in stabilizing the microtubule assembly [35]. We assume
that HDAC6-dependent a-tubulin acetylation contributes to the
decreased cell motility and invasive migration of myeloma cells;
thus, this action of the As2O3-induced a-tubulin acetylation could
be one of the reasons for As2O3 in myeloma treatment. Several
clinical trials have shown the superiority of As2O3 in myeloma
therapy for refractory and relapse MM patients [4,36].
The second HDAC6 substrate is the well-characterized
chaperone Hsp90 [18]. There is evidence that inhibition of
HDAC6 results in increased acetylation of Hsp90 and disruption
of the chaperone association with its client proteins [37]. IKK is a
client of Hsp90 protein complex composed of three subunits,
IKKa (IKK1), IKKb (IKK2) and IKKc (NEMO) [38]. Previous
studies have shown that co-chaperone Cdc37 recruits Hsp90 to the
IKK complex in a transitory manner, preferentially via IKKa
[18]. We firstly hypothesized that As2O3 may trigger Hsp90 down-
regulation. Our results observed that As2O3 resulted in accumu-
lation of acetylated Hsp90 in myeloma cells and inhibition of
chaperone association with IKKa and increased degradation of
IKKa. Importantly, the loss of IKKa-associated Hsp90 occurred
prior to any detectable loss in the levels of IKKa, indicating a
novel pathway by which As2O3 down-regulates HDAC6 to
destabilize IKKa protein via Hsp90 chaperone function. It has
been shown that Hsp90 could be recruited to membrane ruffles,
where deacetylated Hsp90 promotes cell motility [39]. Some
reports showed that specific inhibition of Hsp90 chaperone
function by geldanamycin (GA), an anti-tumor drug, leads to
degradation of its clients [19]. Taken together, our results of
HDAC6-dependent As2O3 action may also be mediated through
arrest cell motility with Hsp90, which has already emerged as a
promising class of anti-cancer drugs in myeloma.
IKK complex directly phosphorylates IkBs (inhibitors of NF-kB)
for subsequent proteasomal degradation, which leads to activation
of NF-kB, a transcription factor family involved in diverse
biological processes [40]. The activation of NF-kB involves the
phosphorylation, ubiquitination, and degradation of IkBa and
phosphorylation of p65, which in turn lead to the translocation of
NF-kB to the nucleus where it binds to specific response elements
Figure 4. As2O3 induces hyperacetylation of Hsp90 and decreases IKKa-binding to Hsp90 by immunoprecipitation and western blot
assays. (A) The accumulation of acetylated Hsp90 in NCI-H929 cells were cultured with As2O3 (0 mM, 2.5 mM, and 5 mM) for 48 hours. (B) Hsp90-IKK
interaction in NCI-H929 cells were cultured with As2O3 (2.5 mM) for 48 hours. (C) The IKKa protein expression in myeloma cells treated with As2O3
(0 mM, 2.5 mM, and 5 mM) for 48 hours.
doi:10.1371/journal.pone.0032215.g004
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required for the transcriptional activation of NF-kB in a number of
ways: by stabilizing p65 protein, regulating DNA-binding activity,
decreasing the binding of p65 to IkBa and enhancing its
transactivation potential [22] .To assess the biologic significance
of NF-kB activation during As2O3-induced growth inhibition, we
were designed to investigate the effects of As2O3 on TNF-a-
induced phosphorylation of Ser-536 p65 NF-kB signaling
pathway. Ser-536 is located in the COOH terminal TAD of p65
and its phosphorylation plays a key role in transcriptional
activation in response to stimuli such as TNF-a [42]. We showed
that, in cells treated with As2O3, phosphorylation of Ser-536 on
NF-kB p65 was significantly reduced in response to TNF-a in
dose- and time- dependent matter. Consistent with our findings in
other types cells [23], TNF-a-induced phosphorylation of Ser-536
on p65 was also significantly reduced in cells, thus attenuating
activation of NF-kB signaling.
In conclusion, this study showed for the first time that As2O3
exerts antimyeloma effects by inhibiting HDAC activity, promot-
ing a-tubulin acetylation, decreasing Hsp90 function, resulting in
NF-kB inactivation. Together, the results in the present study
elaborated a novel molecular mechanism link among As2O3 in
HDAC actively by inhibiting activity in the cytoplasmic substrates
of HDAC6. Thus, our data here thus may provide an important
insight into the molecular mechanism of anti-myeloma activity of
As2O3, and the rationale for As2O3 can be extended readily using
all the HDAC associated diseases.
Materials and Methods
Cells and reagents
Myeloma cell line NCI-H929 secreting the IgA k light chain
was a gift from Dr. Margaret H.L. Ng (Prince of Wales Hospital,
Chinese University of Hong Kong). Cells were cultured in RPMI
1640 medium (Sigma–Aldrich, St. Louis, MO, USA) supplement-
ed with 10% heat-inactivated fetal bovine serum (FBS), 100 U/
mL penicillin, 100 mg/mL streptomycin, and 2 mmol/L l-
glutamine at 37uC in humidified air containing 5% carbon
dioxide. Culture medium was replaced every 3 days. As2O3 power
was purchased from Sigma Co., USA (Lot:A1010) and stored at
room temperature, and then it was diluted in culture media just
before use. All experiments were conducted with cells in
logarithmic phase. TNF-a was purchased from Promega (Madi-
son, WI).
Antibodies
For Western blot, the following antibodies were used: mouse
monoclonal antibodies against Hsp90 antibody (Stressgen Bio-
technology), p65 (Santa Cruz, CA), a-tubulin and anti-b-actin
(Sigma,USA), and anti–IKKa (Imgenex, San Diego, CA).
Phosphospecific anti-p65 (Ser536) antibodies were purchased
from Cell Signaling Technology (Danvers, MA). Anti-acetyl-lysine
antibodies were from Upstate Biotechnology, Inc. (Lake Placid,
NY).
Primary multiple myeloma cells
Primary myeloma cells were isolated from the bone marrow
samples of four MM patients receiving routine diagnostic
aspiration, with informed consent approved by the Institutional
Ethics Committee. Briefly, cells were separated by Ficoll density
gradient centrifugation and washed in phosphate-buffered saline
(PBS) twice prior to incubation with an anti-CD138 antibody
coupled to magnetic beads (Miltenyi Biotechm Aurburn, CA), and
selection using a magnetic affinity column, according to
manufacturer’s recommendation. Purity of the cell preparation
was verified with fluorescence-activated cell-sorting (FACS)
analysis and light microscopy to be at .95%. The fresh purified
MM cells were cultured for overnight to preactivate in RPMI 1640
medium (GIBCO-BRL, Grand Island, NY), supplemented with
10% FBS, 100 U/mL penicillin, 100 mg/mL streptomycin, and
2 mmol/L l-glutamine (GIBCO-BRL) and IL-6 (20 ng/mL; R&D
Systems, Abington, UK) during ex vivo culture.
Cell viability
Cell viability was tested by colorimetric assay kit (CCK-8 assay
kit; Dojindo Laboratories, Tokyo, Japan) based on the MTT
assay, according to the manufacturer’s instructions. Briefly, 5610
3
cells were incubated in 96-well plates with 0.1, 0.5, 1, 2, 4, 8, 16,
32, or 64 mMA s 2O3 treatments in culture medium for different
time points, and then 10 mL of the CCK-8 solution was added to
each well. After 4 hours incubation at room temperature, the
optical density (OD) was measured using a spectrophotometer
(Molecular Devices Co., Sunnyvale, CA) and the fold-increase in
the OD compared to that of the control (proliferation index) was
calculated. All experiments were performed in triplicate.
Detection of Apoptosis
Cell apoptosis was detected by using annexin V staining. MM
cells were cultured in media alone, or with media plus with various
concentration As2O3 treatments in culture medium for 24 and
48 hours. Cells were then washed twice with ice-cold PBS and
resuspended (1610
6 cells/mL) in binding buffer (10 mmol/L
Figure 5. As2O3 inhibits TNF-a dependent p65 phosphoryla-
tion. (A) Cells were either untreated or pretreated with 2.5 mMA s 2O3
for 6 hours and then treated with 10 ng/mL TNF-a for 0, 10, 20, 30, 60,
120 minutes time points. (B) Cells were incubated with 2.5 mM, 5 mM,
7.5 mMA s 2O3 for 6 hours and then treated with 10 ng/mL TNF-a for
20 minutes. Western blot analysis was performed with anti-p65 and
anti-phospho- p65-Ser 536.
doi:10.1371/journal.pone.0032215.g005
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cells (1610
5) were incubated with annexin V-FITC (5 mL;
Pharmingen, San Diego, CA) and PI (5 mg/mL) for 15 minutes
at room temperature. AnnexinV+PI- apoptotic cells were
enumerated by using the flow cytometer (FACS Navios, Beckman
Coulter).
HDAC activity assay
HDAC Activity was performed using the colorimetric HDAC
activity assay from BioVision (BioVision Research Products,
Mountain View, CA, USA) according to manufacturer instruc-
tions. Briefly, 100 mg of nuclear extracts from tumors were diluted
in 85 mL of ddH2O; then, 10 mLo f1 0 6HDAC assay buffer were
added followed by addition of 5 mL of the colorimetric substrate
exposed to different concentration of As2O3; samples were
incubated at 37u for 30 min. Subsequently, the reaction was
stopped by adding 10 mL of lysine developer and left for additional
30 min at 37uC. Samples were read in a fluorescence plate reader
with Ex.=360 nm and Em.=460 nm. Inhibition of HDAC
activity was expressed as inhibition of Relative Fluorescence Units.
Western blot analysis
Cell lysates and total protein concentration was measured with
the BCA Protein Assay Kit (Pierce Biotechnology, Rockford IL,
USA).Equal amounts of protein were subjected to SDS-PAGE and
proteins were transferred to nitrocellulose membranes (GE
Healthcare, USA). The membrane was blocked in PBS containing
5% non-fat milk and 0.1% Tween-20, washed twice in PBS, and
incubated with primary antibody at room temperature for
2 hours, followed by incubation with secondary antibody at room
temperature for 45 minutes. Afterward, the proteins of interest
were visualized using ECL chemiluminescence system (Santa Cruz
Biotechnology, USA).
Immunoprecipitation
To assess the effects of As2O3 on Hsp90 acetylation and the
Hsp90-IKK interaction, cells (5610
6) were treated with As2O3 at
0 mM, 2.5 mMo r5mM for 48 hours. Cells were lysed with cell
lysis buffer [50 mmol/L Tris-HCl (pH 8.0), 150 mmol/L NaCl,
5 mmol/L EDTA, and 1% Triton X-100] or radioimmunopre-
cipitation assay buffer [50 mmol/L Tris (pH 8.0), 150 mmol/L
NaCl, 0.5% deoxycholate, 0.1% SDS, and 1.0% NP-40]
containing 16protease inhibitor cocktail (Roche, Switzerland) at
4uC with gentle rocking.
The supernatant was precleared to block nonspecific binding
with 20 mL protein A-Agarose beads and 20 mL protein G-
Agarose beads (Sigma, USA) that had been prewashed three times
with RIPA buffer before use. Precleared cellular extract was evenly
transferred to 2 new 1.5 mL microcentrifuge tubes. Anti-Hsp90
antibody (2 mL) was added to one microcentrifuge tube and the
same amount of normal preimmune IgG from the same origin was
added to another tube. After 2 hours incubation at 4uC, 20 mL
prewashed protein A-agarose beads and 20 mL prewashed protein
G-agarose beads were added to each tube and immunoprecipi-
tation was performed by rocking overnight at 4uC. The
immunoprecipitates were eluted by the 26SDS sample buffer
and 1% of input and 20% of bound fractions were resolved by
SDS PAGE for western blot analysis with IKKa antibody
(Imgenex) and an acetylated lysine Hsp90 antibody (Upstate
Biotechnology, Lake Placid, NY) as described above.
Statistical analysis
Experiments were repeated minimum 3 times with consistent
results. Data are expressed as the mean plus or minus SD. Analysis
of statistical significance between groups was made using a 2-tailed
unpaired Student’s t test. A value of p,0.05 was considered
statistically significant.
Author Contributions
Conceived and designed the experiments: JH JD. Performed the
experiments: XQ JD. Analyzed the data: CZ WF HX. Contributed
reagents/materials/analysis tools: JZ. Wrote the paper: JH JD.
References
1. Wang ZY, Chen Z (2008) Acute promyelocytic leukemia: from highly fatal to
highly curable. Blood 111: 2505–2515.
2. Sanz MA, Lo-Coco F (2011) Modern approaches to treating acute promyelo-
cytic leukemia. J Clin Oncol 29: 495–503.
3. Emadi A, Gore SD (2010) Arsenic trioxide - An old drug rediscovered. Blood
Rev 24: 191–199.
4. Qazilbash MH, Saliba RM, Nieto Y, Parikh G, Pelosini M, et al. (2008) Arsenic
trioxide with ascorbic acid and high-dose melphalan: results of a phase II
randomized trial. Biol Blood Marrow Transplant 14: 1401–1407.
5. Vey N, Bosly A, Guerci A, Feremans W, Dombret H, et al. (2006) Arsenic
trioxide in patients with myelodysplastic syndromes: a phase II multicenter
study. J Clin Oncol 24: 2465–2471.
6. Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL, Jr., et al. (2011) A
randomized phase 2 trial of a preparative regimen of bortezomib, high-dose
melphalan, arsenic trioxide, and ascorbic acid. LID - 10.1002/cncr.26517 [doi].
Cancer.
7. Miller WH, Jr., Schipper HM, Lee JS, Singer J, Waxman S (2002) Mechanisms
of action of arsenic trioxide. Cancer Res 62: 3893–3903.
8. Hayashi T, Hideshima T, Akiyama M, Richardson P, Schlossman RL, et al.
(2002) Arsenic trioxide inhibits growth of human multiple myeloma cells in the
bone marrow microenvironment. Mol Cancer Ther 1: 851–860.
9. Beauchamp EM, Ringer L, Bulut G, Sajwan KP, Hall MD, et al. (2011) Arsenic
trioxide inhibits human cancer cell growth and tumor development in mice by
blocking Hedgehog/GLI pathway. J Clin Invest 121: 148–160.
10. Dos SGA, Abreu ELRS, Pestana CR, Lima AS, Scheucher PS, et al. (2011)
(+)alpha-Tocopheryl succinate inhibits the mitochondrial respiratory chain
complex I and is as effective as arsenic trioxide or ATRA against acute
promyelocytic leukemia in vivo. LID - 10.1038/leu.2011.216 [doi].
Leukemia.
11. Lemoine M, Younes A (2010) Histone deacetylase inhibitors in the treatment of
lymphoma. Discov Med 10: 462–470.
12. Aldana-Masangkay GI, Sakamoto KM (2011) The role of HDAC6 in cancer.
J Biomed Biotechnol 2011: 875824.
13. Gregoretti IV, Lee YM, Goodson HV (2004) Molecular evolution of the histone
deacetylase family: functional implications of phylogenetic analysis. J Mol Biol
338: 17–31.
14. Verdin E, Dequiedt F, Kasler HG (2003) Class II histone deacetylases: versatile
regulators. Trends Genet 19: 286–293.
15. Tokesi N, Lehotzky A, Horvath I, Szabo B, Olah J, et al. (2010) TPPP/p25
promotes tubulin acetylation by inhibiting histone deacetylase 6. J Biol Chem
285: 17896–17906.
16. Valenzuela-Fernandez A, Cabrero JR, Serrador JM, Sanchez-Madrid F (2008)
HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions.
Trends Cell Biol 18: 291–297.
17. Yao YL, Yang WM (2011) Beyond histone and deacetylase: an overview of
cytoplasmic histone deacetylases and their nonhistone substrates. J Biomed
Biotechnol 2011: 146493.
18. Hinz M, Broemer M, Arslan SC, Otto A, Mueller EC, et al. (2007) Signal
responsiveness of IkappaB kinases is determined by Cdc37-assisted transient
interaction with Hsp90. J Biol Chem 282: 32311–32319.
19. Qing G, Yan P, Xiao G (2006) Hsp90 inhibition results in autophagy-mediated
proteasome-independent degradation of IkappaB kinase (IKK). Cell Res 16:
895–901.
20. Gupta SC, Sundaram C, Reuter S, Aggarwal BB (2010) Inhibiting NF-kappaB
activation by small molecules as a therapeutic strategy. Biochim Biophys Acta
1799: 775–787.
21. Hayden MS, Ghosh S (2008) Shared principles in NF-kappaB signaling. Cell
132: 344–362.
22. Bohuslav J, Chen LF, Kwon H, Mu Y, Greene WC (2004) p53 induces NF-
kappaB activation by an IkappaB kinase-independent mechanism involving
phosphorylation of p65 by ribosomal S6 kinase 1. J Biol Chem 279:
26115–26125.
As2O3 Exerts Antimyeloma Effects by HDAC
PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e3221523. Waxman S, Anderson KC (2001) History of the development of arsenic
derivatives in cancer therapy. Oncologist 6 Suppl 2: 3–10.
24. Kajiguchi T, Yamamoto K, Iida S, Ueda R, Emi N, et al. (2006) Sustained
activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-
induced cell apoptosis in multiple myeloma cell lines. Cancer Sci 97: 540–545.
25. Wen J, Cheng HY, Feng Y, Rice L, Liu S, et al. (2008) P38 MAPK inhibition
enhancing ATO-induced cytotoxicity against multiple myeloma cells.
Br J Haematol 140: 169–180.
26. Roussel RR, Barchowsky A (2000) Arsenic inhibits NF-kappaB-mediated gene
transcription by blocking IkappaB kinase activity and IkappaBalpha phosphor-
ylation and degradation. Arch Biochem Biophys 377: 204–212.
27. Kapahi P, Takahashi T, Natoli G, Adams SR, Chen Y, et al. (2000) Inhibition of
NF-kappa B activation by arsenite through reaction with a critical cysteine in the
activation loop of Ikappa B kinase. J Biol Chem 275: 36062–36066.
28. Nasr R, Rosenwald A, El-Sabban ME, Arnulf B, Zalloua P, et al. (2003)
Arsenic/interferon specifically reverses 2 distinct gene networks critical for the
survival of HTLV-1-infected leukemic cells. Blood 101: 4576–4582.
29. Drobna Z, Jaspers I, Thomas DJ, Styblo M (2003) Differential activation of AP-1
in human bladder epithelial cells by inorganic and methylated arsenicals.
FASEB J 17: 67–69.
30. Davison K, Mann KK, Waxman S, Miller WH, Jr. (2004) JNK activation is a
mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia
cells. Blood 103: 3496–3502.
31. Sharma V, Koul N, Joseph C, Dixit D, Ghosh S, et al. (2010) HDAC inhibitor,
scriptaid, induces glioma cell apoptosis through JNK activation and inhibits
telomerase activity. J Cell Mol Med 14: 2151–2161.
32. Baysan A, Yel L, Gollapudi S, Su H, Gupta S (2007) Arsenic trioxide induces
apoptosis via the mitochondrial pathway by upregulating the expression of Bax
and Bim in human B cells. Int J Oncol 30: 313–318.
33. Zhou L, Jing Y, Styblo M, Chen Z, Waxman S (2005) Glutathione-S-transferase
pi inhibits As2O3-induced apoptosis in lymphoma cells: involvement of
hydrogen peroxide catabolism. Blood 105: 1198–1203.
34. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, et al. (2003) The
deacetylase HDAC6 regulates aggresome formation and cell viability in response
to misfolded protein stress. Cell 115: 727–738.
35. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, et al. (2002) HDAC6 is a
microtubule-associated deacetylase. Nature 417: 455–458.
36. Wu KL, Beksac M, van DJ, Amadori S, Zweegman S, et al. (2006) Phase II
multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in
patients with relapsed or refractory multiple myeloma. Haematologica 91:
1722–1723.
37. Boyault C, Sadoul K, Pabion M, Khochbin S (2007) HDAC6, at the crossroads
between cytoskeleton and cell signaling by acetylation and ubiquitination.
Oncogene 26: 5468–5476.
38. Criollo A, Senovilla L, Authier H, Maiuri MC, Morselli E, et al. (2010) The IKK
complex contributes to the induction of autophagy. EMBO J 29: 619–631.
39. Gao YS, Hubbert CC, Lu J, Lee YS, Lee JY, et al. (2007) Histone deacetylase 6
regulates growth factor-induced actin remodeling and endocytosis. Mol Cell Biol
27: 8637–8647.
40. Karin M (2006) Nuclear factor-kappaB in cancer development and progression.
Nature 441: 431–436.
41. Thu YM, Richmond A (2010) NF-kappaB inducing kinase: a key regulator in the
immune system and in cancer. Cytokine Growth Factor Rev 21: 213–226.
42. Sakurai H, Suzuki S, Kawasaki N, Nakano H, Okazaki T, et al. (2003) Tumor
necrosis factor-alpha-induced IKK phosphorylation of NF-kappaB p65 on serine
536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway.
J Biol Chem 278: 36916–36923.
As2O3 Exerts Antimyeloma Effects by HDAC
PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e32215